C54.2

Clinical Causes: Genetic mutations: Certain genetic changes may increase susceptibility. Hormonal factors: Imbalances in estrogen and progesterone levels could influence risk. Previous pelvic radiation therapy: Exposure to radiation in the pelvic area may increase risk. Age: Incidence tends to rise with advancing age, particularly postmenopausal women. History of other uterine tumors: Prior benign uterine growths may be associated with increased risk. Environmental exposures: Possible links to environmental toxins, though evidence is limited.

Key Symptoms: Abnormal uterine bleeding: Including bleeding between periods or after menopause. Pelvic pain or pressure: Persistent discomfort or sensation of fullness in the pelvis. Unusual vaginal discharge: Especially if foul-smelling or abnormal in appearance. Increase in abdominal size: Due to tumor growth or associated fluid buildup. Difficulty urinating or bowel movements: Resulting from tumor pressing on nearby organs. Unintentional weight loss or fatigue: In advanced stages, systemic symptoms may appear.

Diagnosis Path: Detection of a malignant neoplasm of the myometrium involves several diagnostic procedures, typically starting with a review of symptoms and physical examination. Imaging studies such as ultrasound, MRI, or CT scans help visualize the tumor’s size and location. A definitive diagnosis often requires a biopsy, where tissue samples are examined microscopically for malignant cells. Further staging procedures could include additional imaging to determine if the cancer has spread, guiding treatment decisions.

Treatment Protocols: Treatment options depend on the stage of the tumor, patient health, and preferences. Common approaches include surgical removal of the uterus (hysterectomy), often combined with removal of surrounding tissues or lymph nodes if necessary. This may be followed by radiation therapy, chemotherapy, or targeted therapies aimed at destroying remaining cancer cells. In some cases, hormonal therapy might be considered, especially if the tumor is hormone-sensitive. Supportive care, including pain management and psychosocial support, is also integral to comprehensive care.